T Man Pharmaceutical PCLTMAN
▲ PositiveCapitalrelevance
First-half profit and revenue growth, interim dividend, and CEO's growth outlook support positive sentiment.
Impact on stocks 1
Health Care▲ · 1 stocks
T Man Pharmaceutical PCLTheme Impact 1
Off-coverage companies
Related news
▲
Axsome Says AUVELITY Prescriptions Hit Record as Alzheimer's Launch Grows
Axsome Therapeutics said AUVELITY prescriptions are accelerating after its sales-force expansion and the drug's launch in Alzheimer's disease agitation, with weekly new-to-brand prescriptions reaching a record 3,800. Speaking at Morgan Stanley's Global Healthcare Conference, Chief Financial Officer Nick Pizzie said patients aged 65 and older now account for about 31% of new-to-brand prescriptions, up from roughly 19% before the indication's approval, and that agitation is the fastest-growing segment. Average weekly new-to-brand prescriptions were about 2,400 in the first quarter and 3,000 in the second quarter. Management reiterated its $8 billion long-term peak-sales outlook for AUVELITY, split evenly between $4 billion in major depressive disorder and $4 billion in Alzheimer's disease agitation, and reported 89% coverage of total covered lives, including 100% Medicare coverage. Pizzie said second-quarter selling, general and administrative expense of $208 million should be a reasonable reference point for the back half of the year, while research and development expense of $46 million is expected to rise modestly, and management expects revenue to grow faster than operating expenses on a very clear path toward positive cash flow and profitability.
Teva Study Finds Providers Prioritize Drowsiness Risk When Choosing Tardive Dyskinesia Treatment for Older Patients
Teva Pharmaceuticals announced new data showing that healthcare providers prioritize drowsiness risk, the duration of available long-term response data and drug-drug interaction profile when selecting a VMAT2 inhibitor for tardive dyskinesia in patients aged 55 and older. In a discrete choice experiment, 489 healthcare providers ranked somnolence risk, accounting for 26.8% to 36.2% of decision-making weight, and short-term symptom improvement, at 24.4% to 29.5%, as their top priorities, followed by dose formulation at 16.7% to 20.2% and drug-drug interaction risk at 14.4% to 17.3%. Applying those preferences across four patient profiles, AUSTEDO, also known as deutetrabenazine, had the highest predicted choice probability, driven mainly by somnolence risk, duration of long-term response data and drug-drug interaction. The findings were presented at Psych Congress, held September 15 to 19, 2026, in New Orleans. A separate interim analysis from the IMPACT-TD Registry found that among patients with probable tardive dyskinesia who remained untreated with any VMAT2 inhibitor for 24 months, roughly 89% to 96% experienced at least a mild global impact and 60% to 74% experienced moderate-to-severe impact, while 55% to 69% reported stable or worsening severity with no evidence of spontaneous resolution.
▲5impact 4
Eisai's Subcutaneous Leqembi Wins Health Ministry Approval, Enabling At-Home Dosing
Eisai and U.S. pharmaceutical giant Biogen announced on the 16th that the subcutaneous formulation of their Alzheimer's disease treatment lecanemab, sold under the brand name Leqembi, has received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare. The product, named Leqembi Subcutaneous Injection 250mg Pen, can be administered in about 15 seconds per pen, with two pens used per dose. Until now, patients needed intravenous infusions at a hospital once every two weeks, but the subcutaneous formulation allows once-weekly self-administration at home, though doctor visits will still be required for prescriptions and safety checks. Following deliberation and approval by the Central Social Insurance Medical Council, prescriptions are expected to begin between mid-November and mid-December. This is the third country to approve the subcutaneous version, after the United States and China.